Yes, NMPA (National Medical Products Administration) registration for medical devices in China typically requires a risk assessment report as part of the submission. The risk assessment report is a critical component of the clinical evaluation and risk management process, helping to demonstrate the safety and effectiveness of the device.

The report should outline:

1. Identification of Potential Risks: This includes risks associated with the design, materials, use conditions, and the environment where the device will be used.
2. Risk Control Measures: How risks are minimized or mitigated through design, testing, labeling, or other measures.
3. Post-market Surveillance Plans: How the device's performance will be monitored once it is on the market to identify any unforeseen risks.

The NMPA uses this information to assess whether the device is safe for use by patients and healthcare professionals. The risk assessment report is often integrated into the overall technical documentation submitted during the registration process, alongside other documents such as product descriptions, performance testing reports, clinical trial data (if applicable), and manufacturing details.

For devices that are Class III (high-risk), the risk assessment and clinical data are typically more extensive. The NMPA may also require manufacturers to include information related to ISO 14971 (the international standard for risk management in medical devices).

If you are planning to apply for NMPA registration, it's essential to ensure that the risk assessment is thorough and aligns with the specific requirements outlined by the NMPA and any applicable Chinese regulations.